Search Results

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced the appointment of Niall Condon as president of its Manufacturing Division, with immediate effect.

Curia, a leading contract research, development and manufacturing organization, announced that Gerald Auer has been appointed as chief financial officer.

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand.

Berkeley Lights, Inc., a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

Curia, a leading contract research, development and manufacturing organization, announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan.

Curia today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has dosed the first participant with RBI-4000, a self-replicating (srRNA) rabies vaccine, in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, and Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer and to treat autoimmune and inflammatory disorders and other diseases using self-replicating RNA (srRNA), today announced that they will collaborate on a robust development platform for Replicate’s srRNA therapeutics.

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has completed the transaction to acquire LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts and Texas

Curia today announced that Philip Macnabb has been appointed as chief executive officer, succeeding John Ratliff.

Curia today announced it has signed a licensing agreement with MilliporeSigma, the North American Life Sciences Business of Merck KGaA, Darmstadt, Germany, that enables Curia and its clients to use the CHOZN® GS-/- cell line for production of therapeutic proteins and antibodies.